Drug intelligence / Profile preview

Recombinant Hepatitis B vaccine (AIM Vaccine Co.)

Development stage: Preclinical
Lead developer: AIM Vaccine Co.
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This recombinant Hepatitis B vaccine is a prophylactic agent being developed by AIM Vaccine Co. for the prevention of Hepatitis B virus (HBV) infection. The vaccine is produced using recombinant DNA technology to express the Hepatitis B surface antigen (HBsAg). When administered, it is designed to stimulate the host's immune system to produce specific neutralizing antibodies (anti-HBs), providing active immunity against the virus. According to company pipeline information, this specific recombinant formulation is currently in the preclinical research stage, complementing the company's broader portfolio of viral vaccines.

Other names: Hepatitis B vaccine (recombinant)AIM Hepatitis B vaccine

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on Recombinant Hepatitis B vaccine (AIM Vaccine Co.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombinant Hepatitis B vaccine (AIM Vaccine Co.).

Explore the full profile